Skip to content

Patients › Wrist

डी क्वेरवैन का टेनोसिनोवाइटिस

Patient-facing topic on De Quervain's tenosynovitis (first dorsal compartment) — diagnosis, conservative management, and indications for de Quervain's release.

Updated Sep 2026
हाथ से खींचा गया एक चेहराहीन माता-पिता का चित्र जो एक बच्चे को उठा रहा है, कलाई के अंगूठे की तरफ दर्द।
अंगूठे की टेंडन की शारीरिक रचना जो कि डी क्वेरविन के अपहरणकर्ता पोलिसिस लोंगस और विस्तारक पोलिसिस ब्रेविस में प्रभावित होती है क्योंकि वे कलाई को पार करते हैं। Kieran Hirpara 4.0

यह पृष्ठ मशीन द्वारा अनूदित है और अभी तक किसी चिकित्सक द्वारा जाँचा नहीं गया है। अंग्रेज़ी संस्करण ही आधिकारिक है।

आप क्या महसूस कर रहे हैं

De Quervain's tenosynovitis आपके कलाई के अंगूठे की तरफ, अंगूठे के आधार के पास दर्द का कारण बनता है। यह क्षेत्र कोमल और थोड़ा सूजन भी महसूस कर सकता है। समस्या एक संकीर्ण सुरंग में बैठती है जिसके माध्यम से दो अंगूठे की नसें फिसलती हैं, और जब वह सुरंग चिढ़ जाती है, तो जब वे चलते हैं तो नसें पकड़ लेती हैं।

कुछ आंदोलन दर्द को बढ़ा देते हैं। अपनी कलाई को छोटी उंगली की ओर झुकाना, कलाई को झुकाते हुए कसकर पकड़ना, या अपनी अंगुली और उंगली को एक साथ चिपकाकर यह सब शुरू हो सकता है। जब आप एक केतली उठाते हैं, दरवाजे के हैंडल को मोड़ते हैं, अपने बच्चे को उठाते हैं या कैंची का उपयोग करते हैं, तो आप इसे देख सकते हैं। कुछ लोगों को यह दर्द जागने पर या किसी लम्बी गतिविधि के बाद महसूस होता है।

इसका कारण स्पष्ट रूप से आपकी नौकरी या किसी विशिष्ट चोट से जुड़ा नहीं है। यह कलाई की अन्य समस्याओं के साथ दिखाई दे सकता है, लेकिन अक्सर यह अपने आप विकसित होता है।

आपका सर्जन आमतौर पर आपकी कलाई की जांच करके और यह सुनकर इसका निदान कर सकता है कि दर्द कहाँ स्थित है। जब चित्र स्पष्ट हो तो स्कैन की आवश्यकता नहीं होती है। इमेजिंग का उपयोग केवल तभी किया जाता है जब जांचने के लिए कुछ और हो, जैसे कि कलाई का पुराना फ्रैक्चर या अंगूठे के आधार पर गठिया।

इस स्थिति को समझने वाले अधिकांश लोग पहले सरल उपचार से शुरू करते हैं, और अधिकांश अपने लक्षणों को एक वर्ष के भीतर व्यवस्थित पाते हैं। कोमल सुरंग में एक स्टेरॉयड इंजेक्शन सामान्य पहला कदम है, और यह 73.4% लोगों के लिए दो इंजेक्शन के भीतर काम करता है। अकेले स्प्लिंटिंग इंजेक्शन की तुलना में कम प्रभावी है।

यदि आपका दर्द गंभीर है, या यह आपको उन चीजों को करने से रोकता है जिन्हें आपको करने की आवश्यकता है, तंग सुरंग को खोलने के लिए सर्जरी पर चर्चा की जा सकती है। इसे पहले विस्तारक कक्ष की रिहाई कहा जाता है, और यह मानक उपचार है जब इंजेक्शनों ने पर्याप्त मदद नहीं की है।

वास्तव में क्या हो रहा है

आपके अंगूठे को आपके हाथ से बाहर और दूर ले जाने वाली दो नसें आपकी कलाई के अंगूठे की तरफ एक संकीर्ण सुरंग से गुजरती हैं। टेंडन को चिकनी कॉर्ड और सुरंग को पुली बैंड के रूप में सोचें जो उन्हें हड्डी के करीब रखता है। इस स्थिति में, सुरंग तंग और मोटी हो जाती है, इसलिए कॉर्ड अपनी आसान ग्लाइडिंग खो देते हैं।

टेंडन और सुरंग के बीच घर्षण उस स्थान के अंदर सूजन का कारण बनता है। समय के साथ, टेंडन शीट खुद बदलता हैः यह घना और रेशेदार हो जाता है, और ऊतक एक जेल जैसी गुणवत्ता प्राप्त करता है। टेंडन्स भी चिपचिपा बैंड विकसित कर सकते हैं जो उन्हें सुरंग की दीवार पर चिपकाते हैं। नतीजा एक संकीर्ण, संकीर्ण नहर है, और अंगूठे के हर आंदोलन के माध्यम से सूजन के तारों को खींचता है। यह खींचने से पट्टा में दर्द संवेदकों को जलन होती है, यही कारण है कि ऊपर पढ़ी गई चुटकी और पकड़ने की गति चोट पहुंचाती है।

कुछ लोगों में यह सुरंग स्वाभाविक रूप से संकीर्ण भी हो सकती है। इसके अंदर एक अतिरिक्त दीवार, जो अंतरिक्ष को दो डिब्बों में विभाजित करती है, लगभग एक तिहाई आबादी में मौजूद है, और कुछ लोगों के पास एक ही तंग स्थान को साझा करने वाले अतिरिक्त टेंडन स्लिप हैं। ये भिन्नताएं कुछ लोगों में दोनों कलाई पर पाई जाती हैं, और वे भीड़ को अधिक संभावना बनाती हैं।

इस स्थिति को अक्सर टेनोसिनोवाइटिस कहा जाता है, जो टेंडन अस्तर की सूजन की तरह लगता है। वास्तव में, ऊतक परिवर्तन क्लासिक सूजन की तुलना में पहनने और अपक्षय के करीब हैं। सूजन और मोटाई वास्तविक हैं, लेकिन वे सूजन के एक साधारण फ्लेयर से नहीं बल्कि भार के तहत टूटने वाले टेंडन शीट से आते हैं।

यह दर्द इस बात का संकेत नहीं है कि आपने अत्यधिक उपयोग के कारण अपनी कलाई को नुकसान पहुंचाया है। काम पर हाथ का उपयोग या एक विशिष्ट चोट और इस स्थिति के बीच कोई स्पष्ट संबंध स्थापित नहीं किया गया है। यह महिलाओं में अधिक आम है, और यह कलाई की अन्य समस्याओं जैसे कि कलाई के फ्रैक्चर के बाद सर्जरी के साथ प्रकट हो सकता है।

हम इसके बारे में क्या कर सकते हैं

मैटर प्राइवेट हॉस्पिटल रॉकहैम्पटन में ऊपरी अंगों के सर्जन डॉ. किरण हिरपारा, आपकी स्थिति के अनुरूप कम से कम आक्रामक विकल्पों से शुरू करते हैं। मरीजों को आम तौर पर उनके जीपी द्वारा हमारे क्लिनिक में भेजा जाता है; यदि एक फिजियोथेरेपिस्ट ने सुझाव दिया है कि आप हमें देखें, तो आपको मेडिकेयर छूट के लिए पात्र होने के लिए अपने जीपी से एक रेफरल की आवश्यकता होगी। आपकी पहली यात्रा पर हम एक इतिहास लेते हैं, आपकी कलाई की जांच करते हैं और इमेजिंग की व्यवस्था केवल तभी करते हैं जब कुछ और जांचने की आवश्यकता हो। चूंकि यह समस्या एक नई चोट के बजाय लंबे समय से चली आ रही है, इसलिए हम आमतौर पर गैर-ऑपरेटिव देखभाल से शुरू करते हैं।

पहले कदम वे हैं जो आप स्वयं कर सकते हैं। अंगूठे और कलाई को आराम देने से मदद मिलती है, और अंगूठे की मसालेदार स्प्लिंट अंगूठे और कलाई को स्थिर रखती है ताकि चिड़चिड़ा सुरंग को आराम मिले। जब आप इसे पहनते हैं तो एक स्पिंट दर्द को कम कर सकता है, लेकिन जब जोड़ों को फिर से स्वतंत्र रूप से चलना शुरू हो जाता है तो यह काम नहीं करता है। हाथ चिकित्सा एक इंजेक्शन के लिए जोड़ा जा सकता है, और इस संयोजन परीक्षण पर दर्द को कम करने के लिए दिखाया गया है [2]. ऐसे उपचार भी हैं जिनमें एक औषधीय क्रीम को एक छोटे से विद्युत प्रवाह द्वारा त्वचा में धकेल दिया जाता है, या जहां ध्वनि तरंगों को कोमल क्षेत्र में धक्का दिया जाता है; ये कलाई के कामकाज को बेहतर बना सकते हैं और दर्द को कम कर सकते हैं।

मुख्य चिकित्सा उपचार सुरंग में एक कोर्टिसोन इंजेक्शन है। कोर्टिसोन एक शक्तिशाली विरोधी भड़काऊ दवा है जो टेंडन के आसपास की सूजन को शांत करती है। एक एकल इंजेक्शन ने 82% रोगियों में लक्षणों से राहत दी, और उनमें से आधे से अधिक कम से कम 12 महीने तक लक्षण मुक्त रहे। यदि आपको मधुमेह है, तो एक इंजेक्शन के आपके लिए काम करने की संभावना कम है, लेकिन बार-बार इंजेक्शन लगने से इसका प्रभाव कम नहीं होता है। इंजेक्शन को स्प्लिंट के साथ संयोजित करना अकेले इंजेक्शन की तुलना में बेहतर काम करता है। अन्य इंजेक्शन, जैसे हील्यूरोनिक एसिड या पीआरपी, इस स्थिति के लिए हमारे द्वारा पेश किए जाने वाले उपचार का हिस्सा नहीं हैं।

यदि नॉन-ऑपरेटिव देखभाल ने आपको पर्याप्त राहत नहीं दी है, तो हम सर्जरी के बारे में बात करेंगे। यह ऑपरेशन संकीर्ण सुरंग को मुक्त करता है ताकि टेंडन फिर से स्वतंत्र रूप से स्लाइड कर सकें, और यह तब माना जाता है जब इंजेक्शन और स्प्लिंटिंग ने आपके लक्षणों को हल नहीं किया है। आप हमारे साथ मिलकर कुछ भी निर्णय लेने से पहले हम इस बात पर चर्चा करेंगे कि ऑपरेशन में क्या शामिल है, ठीक होने का तरीका कैसा है और परिणाम क्या हैं।

क्या उम्मीद करें

अधिकांश लोगों के लिए, यह स्थिति समय के साथ ठीक हो जाती है। अधिकतर रोगियों के लक्षण एक वर्ष के भीतर ठीक हो जाते हैं। बहुत से लोग बिना सर्जरी के भी ठीक हो जाते हैं: इस स्थिति वाले केवल एक तिहाई लोगों को दो साल के भीतर एक ऑपरेशन की आवश्यकता होती है, और जब सर्जरी की आवश्यकता होती है, तो यह आमतौर पर पहले वर्ष के भीतर होता है।

उपचार का उद्देश्य उस यात्रा को छोटा करना है। कोर्टीसोन इंजेक्शन के साथ एक छोटी अवधि की स्प्लिंटिंग प्रारंभिक देखभाल का मुख्य आधार है, और यह अधिकांश लोगों के लिए काम करता है। यदि पहला इंजेक्शन मदद करता है लेकिन दर्द वापस आ जाता है, तो दूसरा इंजेक्शन अभी भी एक उचित विकल्प है। बार-बार इंजेक्शन लगाने से सफलता की दर कम हो जाती है, लेकिन वे एक उपयोगी उपकरण बने रहते हैं।

यदि आपको मधुमेह है, तो अन्य लोगों की तुलना में एक ही इंजेक्शन से आपके लक्षण ठीक होने की संभावना कम है। अच्छी खबर यह है कि मधुमेह वाले लोगों में आगे के इंजेक्शन अपना प्रभाव नहीं खोते हैं, इसलिए उपचार को दोहराना फायदेमंद रहता है।

छोटे समूह के लिए सर्जरी आरक्षित है जिसका दर्द इंजेक्शन और स्प्लिंटिंग से कम नहीं होता है। जब ऐसा होता है, तंग सुरंग को छोड़ने से टेंडन को स्थायी राहत मिलती है, और ऑपरेशन में जटिलताओं की दर कम होती है।

आप इस स्थिति के बारे में कैसे सोचते हैं यह भी मायने रखता है। जो लोग सबसे खराब की उम्मीद करते हैं वे अधिक दर्द और कम कार्य की रिपोर्ट करते हैं, इसलिए आगे क्या है, इसकी स्पष्ट तस्वीर आपके जीवन के अनुरूप उपचार चुनने में आपकी मदद कर सकती है। यह चिंता करना कि आपने अत्यधिक उपयोग के कारण अपनी कलाई को नुकसान पहुंचाया है, सबूतों द्वारा समर्थित नहीं है, और यह जानना कि कुछ डर को भड़कने से हटा सकता है।

कोई एकल गारंटीकृत समयरेखा नहीं है। कुछ कलाई एक इंजेक्शन के लिए जल्दी प्रतिक्रिया करते हैं, दूसरों को एक दोहराया खुराक की आवश्यकता होती है, और कुछ सर्जरी पर जाते हैं। जब इस स्थिति को अच्छी तरह से प्रबंधित किया जाता है तो यह होता है कि दर्द कम हो जाता है और टेंडन फिर से स्वतंत्र रूप से फिसल जाते हैं। अकेले छोड़ दिए जाने पर, अधिकतर मामले एक वर्ष के भीतर ही ठीक हो जाते हैं, लेकिन इस बीच आपको असुविधा का प्रबंधन करने में महीनों लग सकते हैं।

किसी से कब मिलना है

यदि आपकी कलाई के अंगूठे की तरफ का दर्द वापस आता रहता है, या यदि यह आपको आराम और स्लिंट के बावजूद अपने सामान्य कार्यों को करने से रोकता है, तो अपने चिकित्सक से परामर्श करें। यदि इंजेक्शंस ने स्थिति को ठीक नहीं किया है, या यदि दर्द इतना गंभीर है कि आप दिन-प्रतिदिन अपने हाथ का उपयोग कैसे सीमित करते हैं, तो एक विशेषज्ञ की समीक्षा के लिए पूछें। कुछ लोगों को उनके लक्षण एक वर्ष के भीतर अपने आप कम हो जाते हैं, लेकिन इंतजार ही एकमात्र विकल्प नहीं है, और उपचार उस खिंचाव को छोटा कर सकता है। यदि आपको अंगूठे या कलाई में नई सुन्नता, झुनझुनी या असामान्य संवेदनाएं मिलती हैं जो सामान्य पैटर्न से मेल नहीं खाती हैं, तो अपनी नियुक्ति में इसका उल्लेख करें, क्योंकि कलाई की अन्य समस्याएं कभी-कभी इस स्थिति की नकल कर सकती हैं।

अधिक गहराई से

यह अनुभाग आपके स्वयं के उपचार निर्णयों के लिए आवश्यक से अधिक है। डी क्वेरवैन का टेनोसिनोवाइटिस अतिरिक्त पढ़ने के लायक है क्योंकि एक छोटे से शारीरिक संस्करण के कारण जो एक ऑपरेशन के बाद असंतोष का अधिकांश हिस्सा है जो अन्यथा विश्वसनीय है, और क्योंकि सबसे अच्छा गैर-ऑपरेटिव परिणाम दो उपचारों के बीच चयन करने के बजाय दो उपचारों के संयोजन से आता है।

संयोजन किसी भी भाग को हराता है

पहला डोरसियल डिब्बा कलाई के अंगूठे की तरफ एक सुरंग में दो टेंडन रखता है। उपचार का उद्देश्य उस सुरंग में सूजन को कम करना और इसके माध्यम से गुजरने वाले भार को कम करना है।

का एक नेटवर्क मेटा-विश्लेषण 823 रोगियों ने निष्कर्ष निकाला कि corticosteroid इंजेक्शन के साथ एक छोटी अवधि के immobilisation प्राथमिक और प्रभावी उपचार बनी हुई हैबाहरी शॉकवेव थेरेपी के साथ एक द्वितीयक विकल्प [1]. सीधे घटकों को देखते हुए, संयुक्त ऑर्थोसिस और कॉर्टिकोस्टेरोइड इंजेक्शन दृष्टिकोण अकेले किसी भी हस्तक्षेप की तुलना में अधिक प्रभावी हैं [2].

यह एक अधिक विशिष्ट निर्देश है "एक स्लिंट का प्रयास करें, फिर एक इंजेक्शन अगर यह विफल रहता है। " साक्ष्य दोनों को एक साथ करने का समर्थन करते हैं, इंजेक्शन के बाद एक परिभाषित छोटी अवधि के लिए स्प्लिंट पहना जाता है।

दूसरा इंजेक्शन अभी भी लेने लायक है

जब लक्षण वापस आते हैं, तो रिफ्लेक्स यह निष्कर्ष निकालना है कि इंजेक्शन विफल हो गए हैं और सर्जरी के लिए आगे बढ़ें। एक बड़े समूह के आंकड़े इसके विपरीत कहते हैं: कई इंजेक्शनों के साथ सफलता दर कम हो जाती है, पुनरावर्ती इंजेक्शन की सफलता की दर उच्च है और यह एक व्यवहार्य नैदानिक विकल्प है [3].

पुनरावृत्ति के साथ घटती सफलता की अपेक्षा की जाती है। लेकिन कम सफलता दर व्यर्थता के समान नहीं है, और दूसरा इंजेक्शन एक विलम्ब रणनीति के बजाय एक उचित कदम है।

वेरिएंट जो सबसे सर्जिकल निराशा की व्याख्या करता है

पहली पीठ की कक्ष की रिहाई प्रभावी है, और जहां यह निराशा होती है वहां आमतौर पर एक विशिष्ट कारण होता है। असंतोष का परिणाम हो सकता है अपूर्ण रिलीज़, टेंडन सबलुक्सेशन, तंत्रिका क्षति, या बस वसूली की अवधि, और एक अज्ञात और अप्रकाशित एक्सटेंसर पोलिसिस ब्रेविस सब्सिडी असंतोष का एक अलग स्रोत है [4].

यह अनपैक करने लायक है क्योंकि यह इस खंड में सबसे उपयोगी तथ्य है। लोगों के एक महत्वपूर्ण अनुपात में कक्ष एक सुरंग नहीं बल्कि दो है, जिसमें एक्सटेंसर पोलिसिस ब्रेविस टेंडन दूसरे के साथ अपने स्वयं के अलग आवरण में चलता है। एक रिलीज़ जो मुख्य डिब्बे को खोलती है और रोकती है वह दूसरी आवरण को बरकरार छोड़ देती है, और इसके अंदर की नस अभी भी संपीड़ित है। कलाई को खोला जाता है, ऑपरेशन वर्णित के रूप में पूरा किया जाता है, और लक्षण बने रहते हैं।

यही कारण है कि दो अन्य सूचीबद्ध कारण भी महत्वपूर्ण हैंः बहुत व्यापक रूप से रिलीज़ करने से कलाई की गति के साथ स्नायुओं को नाली से बाहर निकलने की अनुमति मिलती है, जिससे एक दर्दनाक स्नैप होता है, और रेडियल तंत्रिका की सतही शाखा ऑपरेटिव क्षेत्र पर तुरंत पार हो जाती है। डिब्बे को पूरी तरह से खोला जाना चाहिए, लेकिन अत्यधिक नहीं, एक तंत्रिका के रास्ते में, यही कारण है कि एक स्पष्ट रूप से मामूली ऑपरेशन एक बड़े के रूप में एक ही देखभाल की आवश्यकता है।

विकिरण कलाई पर सब कुछ डी Quervain के नहीं है

इस क्षेत्र में दर्द का एक अंतर जानने योग्य है, क्योंकि उपचार अलग-अलग होते हैं: अंगूठे के आधार पर गठिया, अग्रहस्त के कुछ सेंटीमीटर ऊपर इंटरसेक्शन सिंड्रोम, और रेडियल तंत्रिका की जलन सभी अतिव्यापी क्षेत्र में दर्द पैदा कर सकते हैं। कंधे के अलनेर विचलन के साथ कंधे के ऊपर सीधे स्थानीयकृत कोमलता, जब अंगूठे को हथेली में धकेल दिया जाता है, तो दर्द उसके पड़ोसियों के बजाय कंधे के ढक्कन की ओर इशारा करता है।

संदर्भ

[1] चोंग एचएच, प्रधान ए, ढिंगरा एम, लियोंग डब्ल्यू, हाउ एमवाई, शाह आर। डी क्वेर्विन टेनोसिनोवाइटिस प्रबंधन में प्रगति: यादृच्छिक नियंत्रित परीक्षणों का एक व्यापक नेटवर्क मेटा-विश्लेषण। जे हैंड सर्ज अम. 2024;49(6):557-69. https://doi.org/10.1016/j.jhsa.2024.03.003

[2] कैवेलरी आर, शाब्रुन एसएम, टीएम, चिपचेस एलएस। डी क्वेर्वेन रोग के उपचार में हाथ चिकित्सा बनाम कॉर्टिकोस्टेरॉइड इंजेक्शनः एक व्यवस्थित समीक्षा और मेटा-विश्लेषण। जे हैंड थेर. 2016;29(1):3-11. https://doi.org/10.1016/j.jht.2015.10.004

[3] हसन के, सोहन ए, शी एल, ली एम, वुल्फ जेएम। De Quervain tenosynovitis: एक राष्ट्रीय डेटाबेस का उपयोग करके एकाधिक इंजेक्शन के महामारी विज्ञान और उपयोगिता का मूल्यांकन। जे हाथ सर्ग अ. 2022;47(3):284.e1-284.e6. https://doi.org/10.1016/j.jhsa.2021.04.018

[4] रोगोज़िनस्की बी, लोरी जीएम। डी क्वेरवैन टेंडिनोपैथी के लिए पहली पीठ कक्ष रिलीज के बाद असंतोष। जे हैंड सर्ज अमे. २०१६;४१) ११७-९। https://doi.org/10.1016/j.jhsa.2015.09.003


Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

Anatomy

  • Anatomical variations in the first extensor compartment are clinically relevant to the pathophysiology and treatment of De Quervain's tenosynovitis [1].

Non-Operative Management

  • Corticosteroid injection is the only available nonsurgical treatment that can potentially modify the course of de Quervain's tenosynovitis [2].
  • Corticosteroid injection with a short duration of immobilization is the primary and effective treatment for de Quervain tenosynovitis [14].
  • The success rate for treating De Quervain's tenosynovitis decreases with multiple injections [25].
  • Repeat injections for De Quervain's tenosynovitis have a high rate of success and are a viable clinical option [25].
  • Patients presenting with de Quervain's tenosynovitis may favor initial nonsurgical management [8].

Operative Management

  • Surgical release of De Quervain's tenosynovitis remains the gold standard treatment [6].
  • Longitudinal incision for surgical release offers the advantage of easy identification of the compartment [6].
  • Longitudinal incision for surgical release offers the advantage of more complete releases of tendon sheath and peritendinous adhesions [6].
  • Longitudinal incision for surgical release offers the advantage of less risk of palmar subluxation of tendons [6].
  • Release of the first extensor compartment for refractory de Quervain's disease results in good clinical outcomes with minimal morbidity [12].
  • Endoscopic release of the extensor compartment is an effective and safe procedure for patients with de Quervain's disease who are unresponsive to nonoperative treatments [28].
  • Endoscopic release of the extensor compartment is associated with a slight increase in operation time compared to open release [28].
  • Endoscopic release for de Quervain's tenosynovitis provides earlier improvement after surgery compared with open release [30].
  • Endoscopic release for de Quervain's tenosynovitis is associated with fewer superficial radial nerve complications compared with open release [30].
  • Endoscopic release for de Quervain's tenosynovitis is associated with greater scar satisfaction compared with open release [30].
  • Pulley reconstruction should be considered part of the surgical treatment for de Quervain tenosynovitis [4].
  • Pulley reconstruction for de Quervain tenosynovitis provides satisfactory medium-term results [4].

Patient Factors and Outcomes

  • Patients who scored lower than 40 for physical function had significantly increased odds of eventually undergoing surgical release for de Quervain tenosynovitis [23].
  • Patients who scored higher than 60 for pain interference had significantly increased odds of eventually undergoing surgical release for de Quervain tenosynovitis [23].
  • Addressing misconceptions about the consequences of de Quervain's tenosynovitis and symptom duration allows patients to make informed decisions about treatment [5].

Anatomy & Pathophysiology

Anatomical Variations

  • The EPB tendon is the most dorsal tendon in the first dorsal compartment and can be identified by its distally oriented muscle fibers [15].
  • The APL tendon has no muscular fibers in the area of the first dorsal compartment [15].
  • Separate compartments for the EPB and APL tendons are occasionally found, requiring identification of a septum [15].
  • If the EPB tendon is absent, the floor of the compartment may show a Y-shaped tendinous insertion of the brachioradialis tendon [15].
  • The superficial branch of the radial nerve is expected to be encountered in more than 50% of patients undergoing surgery for De Quervain's tenosynovitis [58].
  • The radial artery courses dorsally just beyond the radial styloid, requiring caution during septum resection [15].

Pathological Mechanisms

  • De Quervain's syndrome is defined as inflammation of the APL and EPB tendons in the first dorsal compartment caused by friction within a tight osteoligamentous tunnel [3].
  • Friction between the APL and EPB tendons leads to compromised blood flow and nutrition, resulting in adhesion development and tendon stenosis [3].
  • De Quervain's syndrome may involve myxoid degeneration, a process where connective tissues are replaced by a gelatinous or mucoid substance [3].
  • De Quervain's syndrome is associated with trauma, extensor carpi ulnaris involvement, ligament instability, and repetitive strain [3].
  • Tenovaginitis in the first extensor compartment is characterized by thickening of the fibrous sheath [11].
  • De Quervain's disease results from anatomical factors associated with mechanical stressors [43].
  • Women are more affected by De Quervain's disease than men due to manual work influencing first compartment dynamics [43].
  • Training intensity is a major factor in determining De Quervain's disease in volleyball players [43].
  • Wrist position influences the excursion of the extensor pollicis brevis tendon [44].
  • Stenosing tenosynovitis causes a significant decrease in maximum velocity during slow fist tasks [48].

Classification

Anatomical Variations and Pathophysiology

  • De Quervain's syndrome is defined as a condition originating when the abductor pollicis longus (APL) and extensor pollicis brevis (EPB) tendons in the first dorsal compartment become inflamed through friction within a tight osteoligamentous tunnel [3].
  • The condition is characterized by compromised blood flow and nutrition, leading to adhesions and tendon stenosis [3].
  • De Quervain's syndrome may represent a myxoid degeneration, defined as a degenerative process where connective tissues are replaced by a gelatinous or mucoid substance [3].
  • Terminology for the condition varies, including tendinosis (degeneration without inflammation), tendinopathy (injury to the tendon), and tenosynovitis (inflammation or thickening of the fibrous sheath wall) [3].
  • De Quervain's syndrome may not be an isolated pathology and has been associated with trauma, extensor carpi ulnaris involvement, ligament instability, and repetitive strain [3].
  • The prevalence of a septated first dorsal compartment is considerably higher in patients with De Quervain tenosynovitis than previously reported [42].
  • An intracompartmental septum between the APL and EPB tendons is present in a mean of 43% of wrists in cadaveric studies, with a range of 20% to 75% [17].
  • The presence of an intracompartmental septum detected by ultrasound is associated with the failure of ultrasound-guided steroid injection [17].
  • In a prospective study, 22 of 30 wrists (73%) that failed nonsurgical treatment and underwent operative release were found to have a separate compartment for the extensor pollicis brevis [32].
  • The prevalence of a separate extensor pollicis brevis compartment in patients failing nonsurgical treatment is significantly higher than in the general population [32].
  • In cases where constriction involves only the extensor pollicis brevis in a separate compartment, exploration of both compartments is advised [18].
  • Radial styloid abnormalities do not affect the outcome of management for de Quervain's disease [10].

Epidemiology and Risk Factors

  • The unadjusted incidence rate of de Quervain's tenosynovitis in a young, active population was 0.94 per 1000 person-years [31].
  • The unadjusted incidence rate for female patients was 2.81 per 1000 person-years, compared with 0.62 per 1000 person-years for male patients [31].
  • The adjusted incidence rate ratio for females, with males as the referent category, was 4.45 (95% CI 4.28, 4.62) [31].
  • The highest incidence rate was observed in the ≥40-year-old group at 1.37 per 1000 person-years [31].
  • The adjusted incidence rate ratio for the ≥40-year-old group, compared to the <20-year-old group, was 3.65 (95% CI 3.26, 4.09) [31].
  • Non-white race is a risk factor for de Quervain's tenosynovitis, with an adjusted incidence rate ratio of 1.31 (95% CI 1.21, 1.42) for black race and 1.17 (95% CI 1.05, 1.25) for other races compared to white race [31].
  • De Quervain's syndrome affects approximately 1.3% of women and 0.5% of men in a population of adults of working age [17].

Diagnostic and Clinical Considerations

  • Routine wrist radiography prior to surgeon evaluation is wasteful as patients do not benefit from the resulting radiologic data [7].
  • Addressing misconceptions about the consequences of de Quervain's tenosynovitis and symptom duration allows patients to make informed treatment decisions [5].
  • Patients with a physical function score lower than 40 or a pain interference score higher than 60 on PROMIS measures had significantly increased odds of undergoing surgical release [23].

Clinical Presentation

Anatomy and Pathophysiology

  • De Quervain's syndrome is defined as a condition where the abductor pollicis longus (APL) and extensor pollicis brevis (EPB) tendons in the first dorsal compartment become inflamed through friction, leading to pain [3].
  • In De Quervain's syndrome, blood flow and nutrition become compromised, causing adhesions that lead to tendon stenosis [3].
  • The condition is referred to by various terminologies including tendinosis, tendinopathy, and tenovaginitis/tenosynovitis [3].
  • Fritz de Quervain described pain over the first dorsal compartment as a tenosynovitis following repetitive activity in 1895 [3].
  • Theodor Kocher described de Quervain's as a "fibrous tendovaginitis" around the same time, noting that his patients lacked a history of repetitive strain [3].
  • The pain in de Quervain's disease is attributed to friction of the EPL and APB against the pulley of zone 7 of the first extensor compartment [35].
  • This friction results in initial tendinopathy followed by reactive thickening of the pulley [35].
  • A septum can be present between the EPB and APL tendons within the first dorsal compartment [35].
  • The EPB tendon is very small in bulk, while the APL has a variable number of tendons in its final portion at insertion [35].
  • De Quervain's syndrome may not be an isolated pathology and may be associated with trauma, extensor carpi ulnaris involvement, ligament instability, or repetitive strain [3].

Clinical Symptoms and Signs

  • Patients with de Quervain's tenosynovitis mostly complain of soreness and tenderness on the radial side of the distal radius [35].
  • Symptoms are exacerbated by ulnar deviation of the thumb [35].
  • Symptoms are exacerbated by a strong grasp combined with flexion and radial deviation of the wrist [35].
  • Symptoms are exacerbated by firm pinching together of the index finger and thumb [35].
  • Physical examination reveals tenderness and swelling directly over the first dorsal compartment [35].
  • Palpation findings include feeling for moving nodularity, tendon rub, or popping directly over the tendon [38].

Diagnostic Testing

  • Finkelstein's test is described as the standard test to confirm the diagnosis of de Quervain's tenovaginitis [35].
  • The WHAT test (wrist hyperflexion and abduction of the thumb) is a more specific and sensitive test to diagnose de Quervain tenosynovitis than Eichhoff’s Test [35].
  • Finkelstein's test is superior to Eichhoff's test in the investigation of de Quervain's disease [38].
  • The clinical diagnosis of de Quervain's tenosynovitis involves pain and tenderness over the radial styloid and either pain at the radial styloid reproduced by resisted thumb extension or a positive Finkelstein's test result [26].
  • Using the asymptomatic thumb as a standard measure to identify the symptomatic thumb's impairments associated with de Quervain's disease may be invalid [39].

Imaging

  • Plain radiographic findings do not routinely predict the need for surgery or alter treatment courses in the initial diagnosis of De Quervain's tenosynovitis [37].
  • In a study of 200 patients, 69.1% had at least one positive radiographic finding, with carpometacartic joint arthritis being the most common finding seen in 30.9% of cases [37].
  • No radiographic findings altered the course of treatment in patients with isolated De Quervain's tenosynovitis [37].

Patient Factors and Perception

  • More negative perceptions of the consequences of de Quervain's tenosynovitis are associated with worse pain and reduced function at baseline in patients awaiting surgical decompression [21].
  • Worse pain catastrophizing is associated with worse pain and reduced function at baseline in patients awaiting surgical decompression of de Quervain's tenosynovitis [21].

Investigations

Imaging

  • Ultrasound is a useful imaging technique for diagnosing de Quervain's disease and provides important information about anatomic variations within the first extensor compartment [40].
  • Ultrasound is a worthwhile preoperative investigation in case of de Quervain's disease [41].
  • Styloid abnormalities do not affect the outcome of management for de Quervain's disease [10].

Anatomical Variations

  • Anatomic variations in the first extensor compartment are clinically relevant in the pathophysiology and treatment of De Quervain's tenosynovitis [1].
  • The presence of a septum does not significantly affect clinical outcomes or complications following endoscopic release for de Quervain's syndrome [20].
  • When the extensor pollicis brevis tendon is associated with thumb interphalangeal joint extension, it is likely to reside in a subcompartment of the first dorsal compartment, particularly in patients with de Quervain's disease [46].

Treatment

Non-Operative

  • Injection of corticosteroids is the only available nonsurgical treatment that can potentially modify the course of de Quervain's tenosynovitis and is the preferred initial treatment [2].
  • One or two local injections of 1 ml triamcinolonacetonide 10 mg/ml provided by general practitioners lead to short-term improvement in participants with de Quervain's tenosynovitis compared to placebo [19].
  • Corticosteroid injections are a useful treatment for de Quervain's tenosynovitis, leading to treatment success 73.4% of the time within 2 injections [13].
  • Pain and clinical outcomes significantly improved after corticosteroid injection in de Quervain's disease [29].
  • Although the success rate for the treatment of De Quervain's tenosynovitis decreases with multiple injections, repeat injections have a high rate of success and are a viable clinical option [25].
  • Patients with diabetes mellitus have a decreased probability of success following a single corticosteroid injection for de Quervain tenosynovitis in comparison to nondiabetic patients [27].
  • The effectiveness of each additional corticosteroid injection does not appear to diminish in patients with diabetes mellitus [27].
  • The presence of an intracompartmental septum detected by ultrasound is associated with the failure of ultrasound-guided steroid injection in de Quervain’s syndrome [17].
  • Providers should remain cognizant that patients presenting with de Quervain's tenosynovitis may favor initial nonsurgical management [8].
  • Addressing misconceptions about de Quervain's tenosynovitis in terms of the consequences for patients and how long their symptoms will last should allow patients to make informed decisions about the treatment that best matches their values [5].
  • The practice of obtaining routine wrist radiography prior to surgeon evaluation is wasteful as patients do not benefit from the resulting radiologic data [7].

Operative

  • Longitudinal incision offers the advantage of easy identification of the compartment, more complete releases of tendon sheath and peritendinous adhesions, and less risk of palmar subluxation of tendons [6].
  • The release of the first extensor compartment for refractory de Quervain's disease resulted in good clinical outcomes with minimal morbidity [12].
  • Endoscopic release of the extensor compartment is an effective and safe procedure in patients with de Quervain's disease who are unresponsive to nonoperative treatments [28].
  • Endoscopic release of the first extensor compartment is associated with a slight increase in operation time compared to open release [28].
  • Pulley reconstruction should be considered part of the surgical treatment for de Quervain tenosynovitis and gives satisfactory medium-term results [4].
  • Anatomic variations are frequently encountered in recalcitrant cases of de Quervain tenosynovitis [50].
  • Examples of anatomic variations encountered in recalcitrant cases include multiple slips of the abductor pollicis longus and the extensor pollicis brevis in its own separate compartment [50].
  • Outcomes for surgical treatment of de Quervain tenosynovitis are generally excellent [50].
  • Complications of surgical treatment for de Quervain tenosynovitis include iatrogenic injury to the superficial branch of the radial nerve, tendon subluxation, complex regional pain syndrome, and recurrence due to incomplete release [50].
  • The dorsal retinaculum is released during surgical treatment to prevent volar tendon subluxation [50].
  • Surgical decompression should be considered if corticosteroid injection fails [17].
  • The volarly based retinacular flap must remain over the released tendons to prevent volar tendon subluxation during surgical release [15].
  • The first dorsal compartment is opened on its dorsoulnar side during surgical release [15].
  • If the abductor pollicis longus and extensor pollicis brevis tendons cannot be easily retracted from the radial styloid, the surgeon should look for additional “aberrant” tendons and separate compartments [15].
  • Releasing the extensor pollicis brevis tendon first and then the abductor pollicis longus usually reveals the presence or absence of a septum [15].
  • If there is no extensor pollicis brevis present, the surgeon should inspect the floor of the compartment for the footprint of the brachioradialis tendon [15].
  • The brachioradialis tendon has a Y-shaped tendinous insertion, and if this is clearly seen, release of this compartment is assured [15].
  • Resection of a pronounced septum is warranted during surgical release, ensuring not to injure the underlying radial artery coursing dorsally just beyond the radial styloid [15].

Complications

Anatomical Variations and Surgical Risks

  • The longitudinal incision technique creates a longer area in which skin scar may make cutaneous nerves more subject to scar adherence [15].
  • The radial artery courses dorsally just beyond the radial styloid and must be avoided during septum resection [15].
  • The volarly based retinacular flap must remain over the released tendons to prevent volar tendon subluxation [15].
  • A longitudinal incision offers a less risk of palmar subluxation of tendons compared to other approaches [6].

Diagnostic and Anatomical Complications

  • Finkelstein's test is a descriptive error that can produce a false positive [9].
  • Extensor pollicis longus tenosynovitis can mimic de Quervain's disease because of its course through the first extensor compartment [9].
  • The prevalence of a separate compartment for the extensor pollicis brevis is significantly higher in patients with unsatisfactory non-operative outcomes than in the general population [32].
  • An intracompartmental septum is present in a mean 43% of wrists in cadaveric studies, with a range of 20 to 75% across different series [17].
  • Patients with diabetes mellitus have a decreased probability of success following a single corticosteroid injection for de Quervain tenosynovitis compared to nondiabetic patients [27].

Recovery

Non-Operative

  • Corticosteroid injection with a short duration of immobilization remains the primary and effective treatment for de Quervain tenosynovitis [14].
  • According to the limited evidence available, injection of corticosteroids is the only available nonsurgical treatment that can potentially modify the course of de Quervain's tenosynovitis and is therefore the preferred initial treatment [2].
  • Corticosteroid injections lead to treatment success 73.4% of the time within 2 injections [13].
  • Most informed patients initially elect symptomatic treatment for de Quervain's disease, and most experience symptom resolution within one year [33].

Operative

  • Endoscopic release for de Quervain's tenosynovitis seems to provide earlier improvement after surgery, with fewer superficial radial nerve complications and greater scar satisfaction, when compared with open release [30].
  • Pulley reconstruction should be considered part of the surgical treatment for de Quervain tenosynovitis, as the technique gives satisfactory medium-term results [4].

Patient Factors and Prognosis

  • Patients who scored lower than 40 for physical function or higher than 60 for pain interference had significantly increased odds of eventually undergoing surgical release for de Quervain tenosynovitis [23].
  • More negative perceptions of the consequences of de Quervain's tenosynovitis and worse pain catastrophizing are associated with worse pain and reduced function at baseline in patients awaiting surgical decompression [21].

Key Evidence

  • [L4] These variations are clinically relevant in the pathophysiology and treatment of De Quervain's tenosynovitis. [1] (10.1016/j.bjps.2016.08.020)
  • [L4] According to the limited evidence available, injection of corticosteroids is the only available nonsurgical treatment that can potentially modify the course of de Quervain's tenosynovitis and is therefore the preferred initial treatment. [2] (10.1016/j.jhsa.2008.12.030)
  • [L4] [3] (10.1177/1758998315599796)
  • [L4] The authors believe the technique gives satisfactory medium-term results and should be considered part of the surgical treatment for de Quervain tenosynovitis. [4] (10.1055/s-0035-1556862)
  • [L3] Addressing misconceptions about de Quervain's tenosynovitis in terms of the consequences for patients and how long their symptoms will last should allow patients to make informed decisions about the treatment that best matches their values. [5] (10.1097/corr.0000000000001577)
  • [L4] Surgical release of De Quervain's tenosynovitis remains the gold standard treatment, and longitudinal incision offers advantage of easy identification of compartment, more complete releases of tendon sheath and peritendinous adhesions and less risk of palmar subluxation of tendons. [6] (10.1007/s12306-018-0585-1)
  • [L3] The practice of obtaining routine wrist radiography prior to surgeon evaluation is wasteful as patients do not benefit from the resulting radiologic data. [7] (10.1055/s-0037-1606124)
  • [L4] Providers should remain cognizant that patients presenting with de Quervain's tenosynovitis may favor initial nonsurgical management. [8] (10.1016/j.jhsg.2024.01.009)
  • [L4] [9] (10.1016/j.jhsa.2014.09.024)
  • [L4] Though considered as a manifestation of de Quervain's disease by some authors, styloid abnormalities do not affect the outcome of management as proved in this study. [10] (10.1007/s11552-010-9258-8)
  • [L4] [11] (10.1054/jhsb.1999.0277)
  • [L4] The release of the first extensor compartment for refractory de Quervain's disease resulted in good clinical outcomes with minimal morbidity. [12] (10.4055/cios.2014.6.4.405)
  • [L3] This study indicates that corticosteroid injections are a useful treatment for de Quervain's tenosynovitis, leading to treatment success 73.4% of the time within 2 injections. [13] (10.1177/1558944716681976)
  • [L1] Corticosteroid injection with a short duration of immobilization remains the primary and effective treatment for de Quervain tenosynovitis. [14] (10.1016/j.jhsa.2024.03.003)
  • [L3] [17] (10.1177/1753193415611414)
  • [L4] In cases with symptoms of de Quervain's syndrome where the constriction involves only the extensor pollicis brevis in a separate compartment, exploration of both compartments is advised. [18] (10.2106/00004623-194931040-00019)
  • [L1] One or two local injections of 1 ml triamcinolonacetonide 10 mg/ml provided by general practitioners leads to improvement in the short term in participants with de Quervain's tenosynovitis when compared to placebo. [19] (10.1186/1471-2474-10-131)
  • [L4] The presence of a septum does not significantly affect clinical outcomes or complications following endoscopic release for de Quervain's syndrome. [20] (10.1177/17531934231214137)
  • [L3] More negative perceptions of the consequences of de Quervain's tenosynovitis and worse pain catastrophizing are associated with worse pain and reduced function at baseline in patients awaiting surgical decompression of de Quervain's tenosynovitis. [21] (10.1097/corr.0000000000000992)
  • [L4] Patients who scored lower than 40 for physical function or higher than 60 for pain interference had significantly increased odds of eventually undergoing surgical release for de Quervain tenosynovitis. [23] (10.1016/j.jhsa.2023.07.005)
  • [L2] Although the success rate for the treatment of De Quervain's tenosynovitis decreases with multiple injections, repeat injections have a high rate of success and are a viable clinical option. [25] (10.1016/j.jhsa.2021.04.018)
  • [L1] [26] (10.1002/14651858.cd005616.pub2)
  • [L4] Patients with diabetes mellitus have a decreased probability of success following a single corticosteroid injection for de Quervain tenosynovitis in comparison to nondiabetic patients, but the effectiveness of each additional injection does not appear to diminish. [27] (10.1016/j.jhsa.2022.02.018)
  • [L4] Endoscopic release of the extensor compartment seems to be an effective and safe procedure in patients with de Quervain's disease who are unresponsive to nonoperative treatments, despite a little increase in operation time. [28] (10.1016/j.bjps.2011.05.015)
  • [L1] Pain and clinical outcomes significantly improved after corticosteroid injection in de Quervain's disease. [29] (10.1016/j.otsr.2019.11.015)
  • [L1] Endoscopic release for de Quervain's tenosynovitis seems to provide earlier improvement after surgery, with fewer superficial radial nerve complications and greater scar satisfaction, when compared with open release. [30] (10.1302/0301-620x.95b7.31486)
  • [L2] [31] (10.1016/j.jhsa.2008.08.020)
  • [L4] Most informed patients initially elect symptomatic treatment for de Quervain's disease, and most experience symptom resolution within one year. [33] (10.1007/s12593-009-0018-3)
  • [L2] [35] (10.1177/1753193412475043)
  • [L4] [37] (10.1055/s-0040-1716522)
  • [L3] [38] (10.1055/s-0038-1626690)
  • [L3] This finding may question the validity of using the asymptomatic thumb as a standard measure to identify the symptomatic thumb's impairments associated with de Quervain's disease. [39] (10.1197/j.jht.2008.03.004)
  • [L5] Ultrasound is a useful imaging technique for diagnosing de Quervain's disease and provides important information about anatomic variations within the first extensor compartment. [40] (10.1136/bcr-2021-242173)
  • [L4] Ultrasound is a worthwhile preoperative investigation in case of de Quervain's disease. [41] (10.1007/s12593-009-0001-z)
  • [L3] The prevalence of a septated first dorsal compartment is considerably higher than previously reported, most notably in patients with De Quervain tenosynovitis. [42] (10.1177/1558944718810864)
  • [L4] [43] (10.1177/0363546504268134)
  • [L4] In vivo EPB tendon excursion measures have been quantified, and wrist position has been found to have an influence on excursion. [44] (10.1016/j.jht.2017.12.004)
  • [L4] When it does, particularly in patients with de Quervain's disease, it is likely to reside in a subcompartment of the first dorsal compartment. [46] (10.1016/j.jhsa.2008.12.015)
  • [L3] Those subjects demonstrate a significant decrease in maximum velocity in slow fist tasks, highlighting the need for comprehensive assessment to ascertain the full extent of functional limitations that can occur in the setting of hand pathology. [48] (10.1177/1558944717729218)
  • [L2] The anatomical findings are consistent with previous studies, with an expectation to encounter the superficial branch of the radial nerve in more than 50% of patients. [58] (10.1055/s-0039-1688700)

References

[1] Surgical anatomy of the first extensor compartment: A systematic review and comparison of normal cadavers vs. De Quervain syndrome patients. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2017. DOI: 10.1016/j.bjps.2016.08.020

[2] Nonsurgical Treatment for de Quervain's Tenosynovitis. The Journal of Hand Surgery. 2009. DOI: 10.1016/j.jhsa.2008.12.030

[3] De Quervain’s syndrome: It may not be an isolated pathology. Hand Therapy. 2015. DOI: 10.1177/1758998315599796

[4] Pulley Reconstruction As Part of the Surgical Treatment for de Quervain Disease: Surgical Technique with Medium-Term Results. Journal of Wrist Surgery. 2015. DOI: 10.1055/s-0035-1556862

[5] Are Patient Expectations and Illness Perception Associated with Patient-reported Outcomes from Surgical Decompression in de Quervain’s Tenosynovitis?. Clinical Orthopaedics & Related Research. 2020. DOI: 10.1097/corr.0000000000001577

[6] Functional outcome of De Quervain’s tenosynovitis with longitudinal incision in surgically treated patients. MUSCULOSKELETAL SURGERY. 2019. DOI: 10.1007/s12306-018-0585-1

[7] Deferring Routine Wrist Radiography Does Not Affect Management of de Quervain Tendinopathy Patients. Journal of Wrist Surgery. 2017. DOI: 10.1055/s-0037-1606124

[8] De Quervain’s Tenosynovitis: As Seen from the Perspective of the Patient. Journal of Hand Surgery Global Online. 2024. DOI: 10.1016/j.jhsg.2024.01.009

[9] Longitudinal Split Tear of the Extensor Pollicis Brevis Tendon: Report of 2 Cases. The Journal of Hand Surgery. 2015. DOI: 10.1016/j.jhsa.2014.09.024

[10] Does Radial Styloid Abnormality in de Quervain's Disease Affect the Outcome of Management?. HAND. 2010. DOI: 10.1007/s11552-010-9258-8

[11] De Quervain’s Disease. Journal of Hand Surgery. 2000. DOI: 10.1054/jhsb.1999.0277

[12] Surgical Release of the First Extensor Compartment for Refractory de Quervain's Tenosynovitis: Surgical Findings and Functional Evaluation Using DASH Scores. Clinics in Orthopedic Surgery. 2014. DOI: 10.4055/cios.2014.6.4.405

[13] Effectiveness of Corticosteroid Injections for Treatment of de Quervain’s Tenosynovitis. HAND. 2016. DOI: 10.1177/1558944716681976

[14] Advancements in de Quervain Tenosynovitis Management: A Comprehensive Network Meta-Analysis. The Journal of Hand Surgery. 2024. DOI: 10.1016/j.jhsa.2024.03.003

[15] Campbell S Operative Orthopaedics 4 Volume Set. EXCISION OF NECROTIC MUSCLES COMBINED WITH NEUROLYSIS OF MEDIAN AND ULNAR NERVES FOR SEVERE CONTRACTURE > SURGICAL TREATMENT OF DE QUERVAIN DISEASE.

[17] Presence of an intracompartmental septum detected by ultrasound is associated with the failure of ultrasound-guided steroid injection in de Quervain’s syndrome. Journal of Hand Surgery (European Volume). 2015. DOI: 10.1177/1753193415611414

[18] AN UNUSUAL FORM OF DE QUERVAINʼS SYNDROME. The Journal of Bone & Joint Surgery. 1949. DOI: 10.2106/00004623-194931040-00019

[19] Randomised controlled trial of local corticosteroid injections for de Quervain's tenosynovitis in general practice. BMC Musculoskeletal Disorders. 2009. DOI: 10.1186/1471-2474-10-131

[20] Prediction of an intracompartmental septum and its effect on outcomes of endoscopic release for de Quervain’s syndrome. Journal of Hand Surgery (European Volume). 2023. DOI: 10.1177/17531934231214137

[21] Which Psychological Variables Are Associated With Pain and Function Before Surgery for de Quervain’s Tenosynovitis? A Cross-sectional Study. Clinical Orthopaedics & Related Research. 2019. DOI: 10.1097/corr.0000000000000992

[23] Association of Patient-Reported Outcomes Measurement Information System Measures With Injection and Surgical Treatment Response in Patients With De Quervain Tenosynovitis. The Journal of Hand Surgery. 2023. DOI: 10.1016/j.jhsa.2023.07.005

[25] De Quervain Tenosynovitis: An Evaluation of the Epidemiology and Utility of Multiple Injections Using a National Database. The Journal of Hand Surgery. 2022. DOI: 10.1016/j.jhsa.2021.04.018

[26] Corticosteroid injection for de Quervain's tenosynovitis. Cochrane Database of Systematic Reviews. 2009. DOI: 10.1002/14651858.cd005616.pub2

[27] Effectiveness of Corticosteroid Injections in Diabetic Patients With De Quervain Tenosynovitis. The Journal of Hand Surgery. 2022. DOI: 10.1016/j.jhsa.2022.02.018

[28] Does endoscopic release of the first extensor compartment have benefits over open release in de Quervain’s disease?. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2011. DOI: 10.1016/j.bjps.2011.05.015

[29] Prospective randomized comparison of ultrasonography-guided and blind corticosteroid injection for de Quervain's disease. Orthopaedics & Traumatology: Surgery & Research. 2020. DOI: 10.1016/j.otsr.2019.11.015

[30] Endoscopicversusopen release in patients with de Quervain’s tenosynovitis. The Bone & Joint Journal. 2013. DOI: 10.1302/0301-620x.95b7.31486

[31] Incidence of de Quervain's Tenosynovitis in a Young, Active Population. The Journal of Hand Surgery. 2009. DOI: 10.1016/j.jhsa.2008.08.020

[32] Treatment of de Quervain tenosynovitis. A prospective study of the results of injection of steroids and immobilization in a splint.. The Journal of bone and joint surgery. American volume. 1991.

[33] Patient-centered care of de Quervain’s disease. Journal of Hand and Microsurgery. 2009. DOI: 10.1007/s12593-009-0018-3

[35] The wrist hyperflexion and abduction of the thumb (WHAT) test: a more specific and sensitive test to diagnose de Quervain tenosynovitis than the Eichhoff’s Test. Journal of Hand Surgery (European Volume). 2013. DOI: 10.1177/1753193412475043

[37] Are Plain X-Rays Necessary in the Diagnosis of De Quervain's Tenosynovitis?. Journal of Wrist Surgery. 2020. DOI: 10.1055/s-0040-1716522

[38] Finkelstein's Test Is Superior to Eichhoff's Test in the Investigation of de Quervain's Disease. Journal of Hand and Microsurgery. 2018. DOI: 10.1055/s-0038-1626690

[39] Bilateral_Thu_mb's_Active_Range_of_Motion_and_Strength_in_de_Quervain's_Disease_S0894113008000483. Journal of Hand Therapy. 2008. DOI: 10.1197/j.jht.2008.03.004

[40] Type II de Quervain’s disease: depicting subcompartmentalisation with ultrasound. BMJ Case Reports. 2021. DOI: 10.1136/bcr-2021-242173

[41] Preoperative ultrasound in de Quervain’s disease: an investigation worth doing. Journal of Hand and Microsurgery. 2009. DOI: 10.1007/s12593-009-0001-z

[42] Prevalence of a Septated First Dorsal Compartment Among Patients With and Without De Quervain Tenosynovitis: An In Vivo Anatomical Study. HAND. 2018. DOI: 10.1177/1558944718810864

[43] De Quervain Disease in Volleyball Players. The American Journal of Sports Medicine. 2005. DOI: 10.1177/0363546504268134

[44] Ultrasound assessment of extensor pollicis brevis tendon excursion in different wrist positions in healthy people. Journal of Hand Therapy. 2019. DOI: 10.1016/j.jht.2017.12.004

[46] Thumb Interphalangeal Joint Extension By the Extensor Pollicis Brevis: Association With a Subcompartment and de Quervain's Disease. The Journal of Hand Surgery. 2009. DOI: 10.1016/j.jhsa.2008.12.015

[48] Dynamic Functional Assessment of Hand Motion Using an Animation Glove: The Effect of Stenosing Tenosynovitis. HAND. 2017. DOI: 10.1177/1558944717729218

[50] Miller S Review Of Orthopaedics. 2. Flexor tendon injury > 5. de Quervain tenosynovitis (Fig. 7.35).

[58] A Prospective Evaluation of the Anatomy of the First Dorsal Compartment in Patients Requiring Surgery for De Quervain's Tenosynovitis. Journal of Wrist Surgery. 2019. DOI: 10.1055/s-0039-1688700

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International


Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees


Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.


Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.